Abstract Background: CRISPR-Cas9 technology is a powerful tool for precise genome editing and is increasingly applied to correct genetic mutations associated with various diseases, including cancer. This system utilizes a single-guide RNA (sgRNA), typically 20 base pairs long and complementary to the target DNA sequence, to direct the Cas9 nuclease for targeted gene activation (knock-in) or repression (knockout). In recent advancements in cancer immunotherapy, CRISPR-Cas9 has been extensively used to enhance the efficacy of Chimeric Antigen Receptor (CAR) T-cell therapy. The development of universal CAR T cells involves the knockout of key genes such as TRAC (T-cell receptor alpha chain), B2M (Beta-2 microglobulin), and PDCD1 (Programmed cell death protein 1), which improves T-cell persistence, immune evasion, and anti-tumor function. Method: In this study, sgRNAs targeting PDCD1, B2M, and TRAC were designed using nine widely recognized AI-driven bioinformatics tools: CHOPCHOP, CRISPOR, GenScript, Benchling, Cas-Designer, E-CRISP, CRISPR-ERA, CRISPRscan, and ATUM gRNA Tool. These platforms use various algorithms and genomic datasets to predict sgRNA candidates with high on-target activity and minimal off-target effects. The selected sgRNAs were assessed based on criteria including GC content, self-complementarity, and exon targeting. Results: The sgRNA design tools consistently identified high-confidence target sites within exon 1 of the PDCD1, TRAC, and B2M genes. For PDCD1 (PD-1), the sgRNA sequence (5′-CACGAAGCTCTCCGATGTGT-3′) was selected as the most optimal candidate, showing strong consensus across all platforms. Similarly, for TRAC, the sgRNA (5′-TCTCTCAGCTGGTACACGGC-3′) targeting exon 1 was chosen based on its high predicted efficiency and specificity. In the case of B2M, the sgRNA (5′-GAGTAGCGCGAGCACAGCTA-3′) was identified as an ideal target site within exon 1, a region critical for MHC class I expression and immune evasion. These sgRNAs demonstrated favorable characteristics including appropriate GC content, minimal self-complementarity, and low predicted off-target activity. To ensure their functional reliability, all selected sgRNAs were validated through an extensive review of scientific literature and previously published patent data, confirming their utility in gene knockout studies related to CAR T-cell enhancement. Conclusion: Among the tools evaluated, CHOPCHOP, Benchling, and CRISPOR emerged as the most comprehensive, offering robust information on GC content, self-complementarity, exon identification, and detailed off-target predictions. Additionally, this study compiled a list of relevant clinical trials involving gene knockouts of PDCD1, TRAC, and B2M to further support the therapeutic relevance of these targets in CAR T-cell development.
Date: | 2025-05-07 |
---|
Authors: | sharma k. |
---|
Ref: | Research Square |
---|